• Risky endeavours for biosimilars market europeanpharmaceuticalreview
    August 10, 2017
    Bringing a biosimilar from early development to market is a risky endeavour say Magnus Franzen (left) and Chris Isler, biosimilar experts at PA Consulting Group…
PharmaSources Customer Service